[go: up one dir, main page]

WO2022006095A3 - Mosaic hiv-1 envelopes to induce adcc responses - Google Patents

Mosaic hiv-1 envelopes to induce adcc responses Download PDF

Info

Publication number
WO2022006095A3
WO2022006095A3 PCT/US2021/039598 US2021039598W WO2022006095A3 WO 2022006095 A3 WO2022006095 A3 WO 2022006095A3 US 2021039598 W US2021039598 W US 2021039598W WO 2022006095 A3 WO2022006095 A3 WO 2022006095A3
Authority
WO
WIPO (PCT)
Prior art keywords
envelopes
hiv
mosaic
responses
mosaic hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/039598
Other languages
French (fr)
Other versions
WO2022006095A2 (en
Inventor
Bette T. Korber
Sandrasegaram GNANAKARAN
Guido FERRARI
Barton F. Haynes
Rory HENDERSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Triad National Security LLC
Original Assignee
Duke University
Triad National Security LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, Triad National Security LLC filed Critical Duke University
Publication of WO2022006095A2 publication Critical patent/WO2022006095A2/en
Publication of WO2022006095A3 publication Critical patent/WO2022006095A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed to mosaic human immunodeficiency virus HIV-1 envelopes, and methods of using the same to induce Antibody (Ab)-dependent cellular cytotoxicity (ADCC) responses. Specifically, the disclosure provides new mosaic HIV-1 envelope designs, selection of HIV-1 envelopes and combinations thereof; methods of using these envelopes to induce antibody protective responses, wherein the protective responses are associated with ADCC activity. Further provided are mosaic HIV-1 envelope sequences, and a pharmaceutical composition comprising a polypeptide of any one of the envelopes or a nucleic acid encoding any one of the envelopes disclosed.
PCT/US2021/039598 2020-06-29 2021-06-29 Mosaic hiv-1 envelopes to induce adcc responses Ceased WO2022006095A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045724P 2020-06-29 2020-06-29
US63/045,724 2020-06-29

Publications (2)

Publication Number Publication Date
WO2022006095A2 WO2022006095A2 (en) 2022-01-06
WO2022006095A3 true WO2022006095A3 (en) 2022-02-03

Family

ID=79315529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/039598 Ceased WO2022006095A2 (en) 2020-06-29 2021-06-29 Mosaic hiv-1 envelopes to induce adcc responses

Country Status (1)

Country Link
WO (1) WO2022006095A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015802A1 (en) * 2013-03-15 2016-01-21 University Of Massachusetts Compositions and methods to treat aids
WO2019070730A1 (en) * 2017-10-02 2019-04-11 Duke University Mosaic hiv-1 envelopes to induce adcc responses
US20190321462A1 (en) * 2015-12-15 2019-10-24 Janssen Vaccines & Prevention B.V. Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015802A1 (en) * 2013-03-15 2016-01-21 University Of Massachusetts Compositions and methods to treat aids
US20190321462A1 (en) * 2015-12-15 2019-10-24 Janssen Vaccines & Prevention B.V. Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
WO2019070730A1 (en) * 2017-10-02 2019-04-11 Duke University Mosaic hiv-1 envelopes to induce adcc responses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEGA EMILIANO RODRíGUEZ: "‘Mosaic’ HIV vaccine to be tested in thousands of people across the world", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 572, no. 7768, 31 July 2019 (2019-07-31), London, pages 165 - 166, XP036853416, ISSN: 0028-0836, DOI: 10.1038/d41586-019-02319-8 *
PARDI NORBERT, LABRANCHE CELIA C., FERRARI GUIDO, CAIN DEREK W., TOMBÁCZ ISTVÁN, PARKS ROBERT J., MURAMATSU HIROMI, MUI BARBARA L.: "Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 15, 15 April 2019 (2019-04-15), US , pages 36 - 47, XP055903201, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2019.03.003 *

Also Published As

Publication number Publication date
WO2022006095A2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
EP4592306A3 (en) Rna constructs and uses thereof
WO2023073190A8 (en) Rna constructs and uses thereof
WO2007084413A3 (en) Methods for treating hepatitis c
Ishag et al. Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein
EP4321217A3 (en) Substituted pyridotriazine compounds and uses thereof
WO2005059107A3 (en) Chemokine receptor binding compounds
WO2022006095A3 (en) Mosaic hiv-1 envelopes to induce adcc responses
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
NO20075752L (en) Chimeric proteins, their preparation and pharmaceutical compositions containing them
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2006138259A3 (en) Chemokine receptor binding compounds
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2004087766A3 (en) Peptabody for cancer treatment
WO2021174132A3 (en) Compositions comprising self-assembling vaccines and methods of using the same
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection
WO2005085268A3 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2006138350A3 (en) Chemokine receptor binding compounds
WO2024075022A3 (en) Rna constructs and uses thereof
WO2006138745A3 (en) Therapeutic peptides and vaccines
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO2021003413A3 (en) Self-assembling circular tandem repeat proteins with increased stability
AU2001278884A1 (en) Anti-hiv and anti-tumor peptides and fragments of lysozyme
CN113166252A (en) Fully human anti-GITR antibody and preparation method thereof
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21832848

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21832848

Country of ref document: EP

Kind code of ref document: A2